Imidazole
Based on 3 publication(s) in Google Scholar
Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.88%
- CAS No.: 288-32-4
- 화학식: C3H4N2
- 분자량:68.08
-
보관:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-15921
IPTGAllolactose Mimic -
HY-B0496
PMSFCathepsin Inhibitor -
HY-K0241
Ni-NTA Magnetic Agarose Beads -
HY-D0857
HEPESZwitterionic Buffer -
HY-15917
DL-DithiothreitolReducing Agent -
HY-B1659
GlycerolEndogenous Metabolite -
HY-Y0966
GlycineNMDAR Agonist -
HY-141415
Tween 20Nonionic Surfactant -
HY-B0239
ChloramphenicolHIF-1α Inhibitor -
HY-D0187
L-Glutathione reducedAntioxidant -
HY-Y0320
Dimethyl sulfoxide, meets analytical specification of Ch.P.Aprotic Solvent -
HY-D0843
N-EthylmaleimideCysteine Residues Modifier
Publications Citing Use of MedChemExpress (MCE) Imidazole
More
Biological Activity
제품 설명
IC50 & Target
|
Human Endogenous Metabolite |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>20 μM
Compound: Imidazole
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 26684853] |
| A549 | IC50 |
>20 μM
Compound: Imidazole
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| CHO | IC50 |
3675 μM
Compound: 20
|
Cytotoxicity against CHO cells after 48 hrs by MTT assay
Cytotoxicity against CHO cells after 48 hrs by MTT assay
|
[PMID: 20634079] |
| HL-60 | IC50 |
>20 μM
Compound: Imidazole
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 26684853] |
| HL-60 | IC50 |
>20 μM
Compound: Imidazole
|
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| MCF7 | IC50 |
>20 μM
Compound: Imidazole
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 26684853] |
| MCF7 | IC50 |
>20 μM
Compound: Imidazole
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| SMMC-7721 | IC50 |
>20 μM
Compound: Imidazole
|
Cytotoxicity against human SMMC7721 cells by MTT assay
Cytotoxicity against human SMMC7721 cells by MTT assay
|
[PMID: 26684853] |
| SMMC-7721 | IC50 |
>20 μM
Compound: Imidazole
|
Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| SW480 | IC50 |
>20 μM
Compound: Imidazole
|
Cytotoxicity against human SW480 cells by MTT assay
Cytotoxicity against human SW480 cells by MTT assay
|
[PMID: 26684853] |
| SW480 | IC50 |
>20 μM
Compound: Imidazole
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
In Vitro
Imidazole (0.01-100 μM, 48 h) shows no inhibitory activityis, but imidazole derivatizations shows significant inhibitory effects in different tumor cell lines[1]. Imidazole (0.01-100 μM, 48 h) has a weak affinity for both EGFR and HER2, whereas the derivatization improves their affinity for these receptors in tumor cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549, HBL-100, HeLa, SW1573, T-47D, WiDr cell lines
-
Concentration:0.01-100 μM
-
Incubation Time:48 h
-
Result:Had no inhibitory activity in the compounds employed as control in different tumor cell lines.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 288-32-4
-
Appearance Solid
-
분자량 68.08
-
화학식 C3H4N2
-
Color White to light brown
-
SMILES
C1=NC=CN1
-
Synonyms
Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
용액&용해도
In Vitro:
DMSO : 100 mg/mL (1468.86 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (36.72 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (36.72 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (1468.86 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
순도&문서
-
Data Sheet (280 KB)
-
SDS (779 KB)
- English - EN (779 KB)
- Français - FR (779 KB)
- Deutsch - DE (779 KB)
- Norwegian - NO (779 KB)
- Español - ES (779 KB)
- Swedish - SV (779 KB)
- Italian - IT (779 KB)
- Korean - KR (779 KB)
- Portuguese - PT (779 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 14.6886 mL | 73.4430 mL | 146.8860 mL | 367.2150 mL |
| 5 mM | 2.9377 mL | 14.6886 mL | 29.3772 mL | 73.4430 mL | |
| 10 mM | 1.4689 mL | 7.3443 mL | 14.6886 mL | 36.7215 mL | |
| 15 mM | 0.9792 mL | 4.8962 mL | 9.7924 mL | 24.4810 mL | |
| 20 mM | 0.7344 mL | 3.6722 mL | 7.3443 mL | 18.3608 mL | |
| 25 mM | 0.5875 mL | 2.9377 mL | 5.8754 mL | 14.6886 mL | |
| 30 mM | 0.4896 mL | 2.4481 mL | 4.8962 mL | 12.2405 mL | |
| 40 mM | 0.3672 mL | 1.8361 mL | 3.6722 mL | 9.1804 mL | |
| 50 mM | 0.2938 mL | 1.4689 mL | 2.9377 mL | 7.3443 mL | |
| 60 mM | 0.2448 mL | 1.2241 mL | 2.4481 mL | 6.1203 mL | |
| 80 mM | 0.1836 mL | 0.9180 mL | 1.8361 mL | 4.5902 mL | |
| 100 mM | 0.1469 mL | 0.7344 mL | 1.4689 mL | 3.6722 mL |
Imidazole Related Classifications
HY-D0837 Related Classifications
Powered by Bioz